The US FDA has approved Eli Lilly’s Foundayo (orforglipron) for adults who are obese or overweight and have medical problems related to their weight. It is the only oral GLP-1 weight loss treatment that can be taken at any time of the day without having to eat or drink.

The GLP-1 weight loss pill can aid in weight loss when combined with a low-calorie diet and increased physical activity.

There are no restrictions on the amount of food or water you can consume, and you can take Foudayo once daily, at any time of day.

The US FDA’s approval was aided by the ATTAIN clinical trial program. With the highest dosage of Foundayo, participants in the ATTAIN-1 trials lost an average of 27.3 pounds (12.4%), whereas those who received a placebo lost only 2.2 pounds (0.9%).

Regardless of whether the trial was completed, participants who took the pill lost an average of 25 pounds while those who took the placebo lost only 5.3 pounds.

Cardiovascular risk indicators, including systolic blood pressure, triglycerides, waist circumference, and non-HDL cholesterol, decreased during Foundayo treatment in the ATTAIN program.

Less than 10% of those who could benefit from a GLP-1 are currently taking one, according to David Ricks, chair and CEO of Eli Lilly and Company. This is due to their inability to obtain one, feelings of shame, difficulty, or belief that their illness is not severe enough to require medical attention.”

“We believe Foundayo can help make things fairer for people who are overweight or obese and have weight-related issues.”

In addition to its use for long-term weight management, Lilly is investigating Foundayo as a treatment for peripheral artery disease, type 2 diabetes, obstructive sleep apnea, osteoarthritis-related knee pain, high blood pressure, and stress urinary incontinence.

“More treatment options mean more choices and help more people get the care they need, whether they are just starting to look for treatment or are looking for a different long-term approach,” stated Joe Nadglowski, president and CEO of the Obesity Action Coalition.

More than 40 nations have requested that Foundayo be approved as a treatment for type 2 diabetes or as a tool for weight loss.